Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trichoderma harzianum
- Development stage
- Unknown
- Lead developer
- ADAMA
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation, Intradermal, Ophthalmic, Topical
01
Overview
Trichoderma harzianum is a naturally occurring fungus widely used as a biocontrol agent in agriculture and horticulture to protect crops from soil-borne diseases, particularly gray mold (Botrytis cinerea). It acts through several mechanisms, including competition for space and nutrients with plant pathogens, direct parasitism of pathogens via the production of hydrolytic enzymes (such as chitinases and glucanases), secretion of antimicrobial compounds, induction of systemic resistance in plants, and enhancement of nutrient uptake. In medicine, extracts are used for allergenic testing due to their ability to provoke immune responses such as increased histamine release and IgG production. The strain T‑39 is specifically registered as an active ingredient in biopesticides. Products containing this fungus are considered safe for humans when used according to label directions but may cause irritation upon direct exposure[1][2][3][4][5][6].
- Brand names
- Binab TTRICHODEX
- Other names
- Trichoderma harzianum extractTrichoderma harzianum wholeHypocrea lixiiSPOROTRICHUM NARCISSITRICHODERMA NARCISSITrichoderma harzianamTrichoderma harzianum ATTC
02
Targets
CWP (Fungal cell wall surface protein)β-glucan (Beta-glucan)
Beyond the preview
Go deeper on Trichoderma harzianum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trichoderma harzianum.